𝔖 Bobbio Scriptorium
✦   LIBER   ✦

704 Longitudinal safety and immunogenicity of a therapeutic cocaine vaccine

✍ Scribed by T.R. Kosten; J.St.Clair Roberts; J. Bond; J. Shields; D. Wood; L. Jack; T. O'Neill; B. Fox

Book ID
117511776
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
139 KB
Volume
60
Category
Article
ISSN
0376-8716

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A therapeutic vaccine for nicotine depen
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity
✍ Patrik Maurer; Gary T. Jennings; JΓΆrg Willers; Franziska Rohner; Ylva Lindman; K πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 254 KB

Nicotine is the principal addictive component in tobacco, and following uptake acts in the central nervous system. The smoking-cessation efforts of most smokers fail because a single slip often delivers sufficient nicotine to the brain to reinstate the drug-seeking behaviour. Blocking nicotine from

Safety and immunogenicity of a recombina
Safety and immunogenicity of a recombinant hepatitis B vaccine
✍ E. Dandolos; A. Roumeliotou-Karayannis; S. C. Richardson; Prof. G. Papaevangelou πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.